Emergent BioSolutions | EBS - Gewinn Vor Steuern

Aktienkurs
8.81
Täglich Wechseln
0.19 2.20%
Monatlich
10.13%
Jährlich
94.05%
Q2 Prognose
8.43




Gewinn Vor Steuern Veränderung Datum
Acadia Pharmaceuticals USD 26.32M 18.28M 2025-12
Akebia Therapeutics USD -11.24M 12.39M 2025-12
ALKERMES USD 100.74M 4.1M 2025-09
Alnylam Pharmaceuticals USD 161.14M 77.83M 2025-12
Amarin USD -852K 7.26M 2025-12
ANI Pharmaceuticals USD 49.52M 39M 2025-09
BioMarin Pharmaceutical USD -26.32M 324.19M 2025-09
Coherus Biosciences USD -46.35M 90.86M 2025-12
Exelixis USD 252.69M 275K 2025-12
Glaxosmithkline GBP 2.46B 569M 2025-09
Heron Therapeutics USD -2.95M 14.54M 2025-12
Ionis Pharmaceuticals USD -228M 99M 2025-12
Ironwood Pharmaceuticals USD 68.02M 30.2M 2025-09
Lexicon Pharmaceuticals USD -12.77M 16.02M 2025-09
Lonza CHF 624M 197M 2024-12
Merck USD 6.74B 22M 2025-09
Moderna USD -187M 631M 2025-09
Myriad Genetics USD 4.6M 3.4M 2025-12
Nektar Therapeutics USD -34.7M 2.35M 2025-12
Neurocrine Biosciences USD 239.4M 52.4M 2025-12
Pacira USD 9.52M 11.45M 2025-09
Pfizer USD 3.33B 290M 2025-09
PTC Therapeutics USD -139.08M 116.01M 2025-12
Sanofi EUR -1.16B 5.5B 2025-12
Sarepta Therapeutics USD -407.67M 213.63M 2025-12
United Therapeutics USD 444M 6M 2025-12
Vanda Pharmaceuticals USD -22.92M 16.68M 2024-12
Xoma USD 15.98M 24.58M 2024-06